Copenhagen, Denmark

Morten A Karsdal

This inventor holds 30 USPTO granted patents and 48 published patent applications, plus 1 CIPO patent and 35 EPO patents, primarily in Biomarker Assays. Top assignees: Nordic Bioscience A/s, Keybioscience Ag, Merck Patent Gmbh. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Morten A Karsdal. Retrieved from https://idiyas.com/inventor/morten-a-karsdal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 30 

% Patents Active = 76.7

 

 

Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 61(Granted Patents)


Location History:

  • København Ø, DK (2012)
  • Kobenhavn, DK (2017)
  • Kobenhavn O, DK (2016 - 2019)
  • Copenhagen, DK (2015 - 2022)
  • Kobenhavn Ø, DK (2019 - 2022)

Company Filing History:


Years Active: 2012-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Biochemical Markers
Collagen Assay
CVD Risk Assessment
Inflammatory Biomarkers
Fibrosis Assay
Metabolic Biomarkers
Peptide Analogs
Neo-Epitope Assay
Pathology Measurement
Osteoarthritis Treatment
Diagnostic Peptides
30 patents (USPTO):Explore Patents

Title: Morten A. Karsdal: Innovator in Biopharmaceuticals

Introduction

Morten A. Karsdal, located in Copenhagen, Denmark, is a well-respected inventor in the field of biopharmaceuticals, holding an impressive 21 patents to his name. His contributions significantly enhance the understanding and treatment of cartilage disorders, showcasing his dedication to innovation in medical science.

Latest Patents

Karsdal has recently developed two notable patents. The first is the "Collagen Type X Alpha-1 Assay," which pertains to a specific antibody that reacts with an epitope of collagen type X alpha 1 in the NC1 domain. This invention allows for the detection of this epitope in biological samples, providing vital information for medical diagnostics. The second patent involves "Metabolic Biomarkers for Predicting Responsiveness to FGF-18 Compound." This invention focuses on biomarkers related to clinical responses when treating cartilage disorders with the FGF-18 compound, enabling healthcare professionals to better predict patient responses and personalize treatment plans.

Career Highlights

Throughout his career, Karsdal has made significant strides in the biopharmaceutical industry. He has been associated with leading companies such as Nordic Bioscience A/S and Keybioscience AG. His work in these organizations has facilitated advancements in understanding cartilage-related diseases and improved therapeutic approaches.

Collaborations

Karsdal has collaborated with notable professionals in his field, including Efstathios Vassiliadis and Kim Henriksen. These partnerships have proven fruitful in driving innovative research and development in biopharmaceuticals, further enhancing Karsdal's contributions to the industry.

Conclusion

Morten A. Karsdal's work continues to push the boundaries of innovation in the treatment of cartilage disorders. With his extensive list of patents and collaborations with esteemed colleagues, he remains a pivotal figure in the reach for new and effective therapies in biomedicine. His inventions not only provide new diagnostic tools but also promise improved patient outcomes in the field of treatment for cartilage disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…